Clinical & Scientific

With a strong cash runway and pivotal trials underway, Sionna Therapeutics aims to revolutionize CF treatment with a novel class of NBD1 stabilizer drugs.

Childhelp co-founder Sara O'Meara receives a lifetime achievement award, highlighting a new partnership and the ongoing fight to protect vulnerable children.

Backed by major VCs, Salma Health is launching integrated centers using AI and advanced therapies to revolutionize neurological and psychiatric care.

With new strategic leaders from Roche and capital markets, GATC Health aims to embed its AI risk prediction tool into pharma R&D and biotech investing.

As Matricelf presents its breakthrough therapy at a major summit, the company moves closer to human trials, offering new hope for paralysis patients.

After a strong 2025, Viatris unveils a plan for $650M in savings, a 10% workforce cut, and a focus on six new drugs to fuel future innovation.

A newly identified blood biomarker for the drug masitinib could revolutionize how doctors treat ALS, progressive MS, and Alzheimer's disease.

Intellia Therapeutics prepares for a critical March, where it will outline its gene editing future to investors amid safety questions and market pressures.

NorthX Biologics and Demeetra have partnered to offer a streamlined, royalty-free path from gene to GMP, tackling key bottlenecks for biotech startups.

A Korean firm says it can cure 34 diseases using cells from cloned embryos, walking a fine line between a medical breakthrough and a bioethical taboo.

iRegene Therapeutics hits dual milestones, advancing AI-derived cell therapies for Parkinson's in the US and Multiple System Atrophy in China.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

Armed with $320M in new capital, Anteris will showcase its revolutionary biomimetic heart valve to top investors. Can it disrupt a market of giants?

Sōlaria Biō’s new study validates a microbe-based medical food, Bōndia™, offering a novel, science-backed approach to bone loss for millions of women.

With impressive preliminary sales and key pipeline updates, Mirum Pharmaceuticals' upcoming earnings call will focus on its strategy for sustained growth in 2026.

With $3.7M in new capital, Sift Biosciences is developing a novel immunotherapy to awaken the body's memory T cells against hard-to-treat diseases.

A novel drug candidate targeting treatment-resistant kidney disease has begun its long journey through clinical trials, signaling a major strategic push.

As Adagene presents at key conferences, its SAFEbody tech and lead drug muzastotug draw focus amid a strategic push for funding and partnerships.

A new FDA approval allows a lung cancer therapy to be given just once a month, a major shift promising to reduce clinic time and improve quality of life.

A new five-year deal will leverage patient-derived stem cells and AI to revolutionize the hunt for Alzheimer's cures, aiming to bridge a critical gap.